Published on March 22, 2010 at 9:40 AM
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) will fully redeem on April 21,
2010 all of its remaining outstanding 3.25% Convertible Senior
Subordinated Notes due 2023 (the “Notes”) pursuant to the terms of the
indenture under which the Notes were issued in September 2003. The
aggregate principal amount currently outstanding of the Notes is
$60,467,000. The CUSIP number for these Notes is 671040 AD 5.
In accordance with the terms of the indenture, the Notes will be
redeemed at 5:00 p.m. (New York City time) on April 21, 2010, at a
redemption price of $1,000 per $1,000 principal amount of Notes, plus
accrued and unpaid interest to, but excluding, April 21, 2010, after
which interest will cease to accrue.
At any time prior to 5:00 p.m. (New York City time) on April 21, 2010,
in accordance with the terms of the indenture, holders may convert their
Notes into shares of OSI Pharmaceuticals common stock at a price of
$50.02 per share, or 19.9925 shares of OSI Pharmaceuticals common stock
per $1,000 principal amount of the Notes. Also in accordance with the
terms of the indenture, a converting holder of Notes will not be
entitled to receive any accrued and unpaid interest, if any, on any
Notes being converted, and no adjustments in respect of payments of
interest, if any, on Notes surrendered for conversion or any dividends
or distributions on OSI Pharmaceuticals common stock issued upon
conversion will be made upon conversion of the Notes. Cash will be paid
in lieu of fractional shares. Any Notes not so converted will be
automatically redeemed on April 21, 2010.
The Bank of New York Mellon, the trustee for the Notes under the
indenture, is mailing a Notice of Redemption to all registered holders
of the Notes today. Copies of such Notice of Redemption and additional
information relating to the procedure for redemption and/or conversion
of the Notes may be obtained from The Bank of New York Mellon by calling
1-800-438-5473.
Source OSI Pharmaceuticals